BioSpace News Archive

Genetown

Voyager Therapeutics Announces Closing of Public Offering of Common Stock

The aggregate net proceeds before expenses to Voyager from the offering are approximately $58.4 million, after deducting underwriting discounts and commissions.

November 13, 2017

·

4 min read

Drug Development

Three-Year Follow-Up Phase III Data Provide Additional Information on Efficacy, Durability and Safety Of Investigational LUXTURNA (Voretigene Neparvovec) in Patients With Biallelic RPE65-Mediated Inherited Retinal Disease

Data show mean improvement demonstrated at one year post one-time administration maintained through at least three years for original intervention cohort, and two years for crossover cohort, with observation ongoing.

November 13, 2017

·

12 min read

Business

Skyline Medical to Hold Business Update Conference Call on November 15, 2017

Management will hold a conference call to provide a business update and host a discussion on recent and upcoming milestones.

November 13, 2017

·

1 min read

BioMidwest

ARKRAY USA Announces the Availability of the GLUCOCARD Shine XL Blood Glucose Monitoring System

ARKRAY USA, a leader in diabetes care products, announced today that the GLUCOCARD Shine XL, ARKRAY’s newest BGMS, is now being shipped to customers in the U.S.

November 13, 2017

·

1 min read

Genetown

eXIthera Presents Clinical Data on Novel Small Molecule FXIa Inhibitor EP-7041 at American Heart Association

Results from the study were highlighted in a poster presentation on November 13 at the American Heart Association Scientific Sessions 2017, in Anaheim, California.

November 13, 2017

·

3 min read

Drug Development

Novartis Brolucizumab (RTH258) Demonstrates Superiority Versus Aflibercept in Key Secondary Endpoint Measures of Disease Activity In nAMD, a Leading Cause of Blindness.

The results of the head-to-head trials, HAWK and HARRIER, were presented at the American Academy of Ophthalmology 2017 Annual Meeting

November 13, 2017

·

14 min read

Drug Development

Corvus Pharmaceuticals Announces Updated Clinical Data from Phase 1/1b Study of CPI-444 and Biomarker Data for Potential Use in Patient Selection

Results showed a response rate of 14 percent (two partial responses, one of which was unconfirmed) with single agent CPI-444 and 13 percent (two confirmed partial responses) for the combination therapy.

November 13, 2017

·

11 min read

Drug Development

Argos Therapeutics Provides Update on Immunology Data from the Phase III ADAPT Trial Presented at the SITC 2017 Annual Meeting

The presentation is focused primarily upon immunology data from the ADAPT clinical trial and includes both new data and an update to data that was previously presented at the European Society of Medical Oncology Conference in September.

November 13, 2017

·

9 min read

Business

Punjab Province in Pakistan Signs Agreement With Novartis Access Against Chronic Diseases

Poor patients in the province of Punjab will soon have free access to high-quality medicines from the Novartis Access portfolio targeting four key noncommunicable disease areas.

November 13, 2017

·

6 min read

Genetown

CRISPR Therapeutics Highlights New Additions to Portfolio of Allogeneic CRISPR-based CAR-T Therapies at SITC Annual Meeting

CRISPR believes that its CAR-T cells therapies may have distinct advantages over the current generation of autologous cell therapies.

November 13, 2017

·

6 min read